Breaking News Instant updates and real-time market news.

NVAX

Novavax

$5.52

-0.08 (-1.43%)

07:03
06/27/19
06/27
07:03
06/27/19
07:03

Novavax confirms accelerated approval pathway available for licensure of NanoFlu

Novavax will utilize the accelerated approval pathway for licensure for NanoFlu, its nanoparticle seasonal influenza vaccine candidate. The FDA acknowledged that the accelerated approval pathway is available to Novavax for its NanoFlu vaccine. Novavax expects to initiate its pivotal Phase 3 clinical trial by the fall of 2019 with top-line clinical data expected in 1Q20. These immunogenicity data are expected to support a U.S. biologics license application. Novavax will conduct an End-of-Phase 2 meeting with the FDA in Q3 to discuss the proposed Phase 3 clinical trial design and other topics that will support the future BLA. The accelerated approval pathway enables Novavax to conduct a non-inferiority immunogenicity clinical trial against a licensed quadrivalent comparator, with a commitment to confirm efficacy post-licensure. "The accelerated approval pathway, combined with the strategic partnership we announced today with Catalent Biologics, allow us to efficiently and cost effectively complete the clinical development of NanoFlu through BLA and licensure," said Novavax CEO Stanley C. Erck. "The Catalent deal provides an $18M cash infusion and flexible manufacturing capacity, supported by the experienced professionals transferred from Novavax to Catalent."

  • 28

    Jun

NVAX Novavax
$5.52

-0.08 (-1.43%)

03/19/19
SBSH
03/19/19
NO CHANGE
Target $1.25
SBSH
Buy
Citi cuts Novavax target to $1.25, sees three reasons to keep Buy
Citi analyst Joel Beatty lowered his price target for Novavax to $1.25 from $3.50 but maintains a Buy rating on the shares. While the recent failure of the Phase 3 respiratory syncytial virus vaccine trial was a "major setback" for the company, three potential upside opportunities collectively make the stock a Buy, Beatty tells investors in a research note. These include an accelerated approval pathway being confirmed by the FDA for NanoFlu, a scenario the analyst believes is "slightly more likely than not," a ResVax partnership is announced, and/or ResVax receiving approval in Europe.
03/19/19
HCWC
03/19/19
NO CHANGE
Target $2
HCWC
Buy
H.C. Wainwright sees pathway for Novavax approval, keeps $2 price target
Following the company's Q4 results and business update, H.C. Wainwright analyst Vernon Bernardino continues to believe a "strong investment thesis remains" for buying Novavax shares. The Prepare trial showed ResVax was safe, and importantly, resulted in clinically meaningful outcomes, Bernardino tells investors in a research note. While the stock remains down 76% from its closing price of $2.13 prior to the Prepare results, prospects for discussions with the FDA and European Medicines Agency, which are expected in the next 90 days, are positive, contends the analyst. He believe ResVax's pathway to approval is "under-appreciated" and would be a buyer of the stock. Bernardino keeps a Buy rating on Novavax with a $2.00 price target. The stock in midday trading is down fractionally at 52c.
05/06/19
SBSH
05/06/19
NO CHANGE
Target $0.95
SBSH
Buy
Citi recommends buying Novavax ahead of regulatory update
Citi analyst Joel Beatty recommends buying Novavax because he sees a "favorable likelihood" that a regulatory update in the next month or so will reveal that the company can pursue the accelerated approval pathway for its flu vaccine. This would allow for Phase 3 results around January 2020, Beatty tells investors in a research note. The analyst sees ~25% upside / ~50% downside on whether accelerated approval is granted. He lowered his price target for Novavax shares to 95c from 95c from $1.25 and keeps a Buy rating on the shares.
05/13/19
OPCO
05/13/19
NO CHANGE
Target $25
OPCO
Outperform
Novavax price target raised to $25 from $1.25 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Novavax to $25 from $1.25 to reflect the company's 1-for-20 stock split, effective May 10. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/19/19
07/19
16:20
07/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCBP

BCB Bancorp

$12.71

-0.09 (-0.70%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Earnings
BCB Bancorp reports Q2 EPS 30c, consensus 30c »

Net interest margin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNXM

CNX Midstream Partners

$14.30

-0.205 (-1.41%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Hot Stocks
CNX Midstream Partners raises quarterly distribution 3.6% to 38.65c per unit »

CNX Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$7.25

0.22 (3.13%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Syndicate
Breaking Syndicate news story on Tellurian »

Tellurian files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
07/19/19
07/19
16:15
07/19/19
16:15
General news
Breaking General news story  »

Boston Federal Reserve…

ROKU

Roku

$106.83

-2.18 (-2.00%)

16:13
07/19/19
07/19
16:13
07/19/19
16:13
Conference/Events
Roku management to meet with Oppenheimer »

Bull/Bear Luncheon to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 07

    Aug

EHTH

eHealth

$86.91

-0.59 (-0.67%)

16:12
07/19/19
07/19
16:12
07/19/19
16:12
Initiation
eHealth initiated  »

eHealth initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 14

    Aug

JEF

Jefferies Financial Group

$20.95

-0.13 (-0.62%)

16:11
07/19/19
07/19
16:11
07/19/19
16:11
Conference/Events
Jefferies Financial Group management to meet with Oppenheimer »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

XXII

22nd Century

$1.94

0.04 (2.11%)

16:10
07/19/19
07/19
16:10
07/19/19
16:10
Hot Stocks
22nd Century: FDA accepts, files MRTP application for VLN cigarettes »

22nd Century announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOI

Solaris Oilfield

$13.12

(0.00%)

16:10
07/19/19
07/19
16:10
07/19/19
16:10
Earnings
Solaris Oilfield reports preliminary Q2 revenue $63M-$65M, consensus $58.04M »

"Our second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Aug

CCNE

CNB Financial

$26.76

0.12 (0.45%)

16:05
07/19/19
07/19
16:05
07/19/19
16:05
Earnings
CNB Financial reports Q2 EPS 64c, two estimates 58c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.81

-0.0999 (-10.98%)

16:05
07/19/19
07/19
16:05
07/19/19
16:05
Hot Stocks
Caxton Corp reports 5.3% passive stake in Sunesis »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRI

Herc Holdings

$40.28

-0.62 (-1.52%)

16:04
07/19/19
07/19
16:04
07/19/19
16:04
Hot Stocks
Gabelli reports 18.15% stake in Herc Holdings »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GMAB

Genmab

$18.08

-0.12 (-0.66%)

15:55
07/19/19
07/19
15:55
07/19/19
15:55
Hot Stocks
Genmab discloses BlackRock stake in company reached 5% »

Genmab A/S announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

DISH

Dish

$40.69

-0.13 (-0.32%)

15:45
07/19/19
07/19
15:45
07/19/19
15:45
Options
Dish call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$19.04

0.5 (2.70%)

15:35
07/19/19
07/19
15:35
07/19/19
15:35
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

15:35
07/19/19
07/19
15:35
07/19/19
15:35
General news
Action Economics Survey results: »

Action Economics Survey…

15:35
07/19/19
07/19
15:35
07/19/19
15:35
General news
Treasury Market Outlook »

Treasury Market Outlook:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.